Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection

Keyphrases

• Antibiotics 100%
• Lower Respiratory Tract Infection 100%
• Pharmacoeconomic Analysis 100%
• Clarithromycin 80%
• Adverse Drug Events 60%
• Cost-effectiveness Analysis 60%
• Cefaclor 60%
• Clinical Response 40%
• Amoxicillin-clavulanate 40%
• Cost-effectiveness 40%
• Acute Exacerbation of Chronic Bronchitis 40%
• Ampicillin 40%
• Erythromycin 40%
• Cefepime 40%
• Cefixime 40%
• Clinical Management 20%
• United States 20%
• Patient Satisfaction 20%
• Safety Data 20%
• Outpatient Setting 20%
• Treatment Failure 20%
• Pharmacy 20%
• Managed Care 20%
• Pneumonia 20%
• Mean Cost 20%
• Practice Guidelines 20%
• Overall Cost 20%
• Sinusitis 20%
• Outpatient Clinic 20%
• Medical Staff 20%
• New Antibiotics 20%
• Randomized Double-blind Controlled Clinical Trial 20%
• Antibiotic Treatment 20%
• Therapeutics Committee 20%
• Comparative Cost 20%
• Community-acquired 20%
• Response Cost 20%
• Formulary 20%
• Drug Acquisition Cost 20%
• Least Cost 20%
• Pharmacoeconomic Model 20%
• Chronic Pneumonia 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Antibiotics 100%
• Lower Respiratory Tract Infection 100%
• Pharmacoeconomics 100%
• Clarithromycin 80%
• Adverse Drug Reaction 60%
• Cefaclor 60%
• Amoxicillin 40%
• Clavulanic Acid 40%
• Chronic Bronchitis 40%
• Ampicillin 40%
• Erythromycin 40%
• Cefixime 40%
• Cefuroxime 40%
• Controlled Clinical Trial 20%
• Sinusitis 20%